Auvelity approval europe or poland or ema?

Has Auvelity been approved in Europe, Poland, or by the EMA?

Auvelity (dextromethorphan/bupropion) is an EU medicine, but the key point for where it’s approved is how the European approval works:

- The EMA (European Medicines Agency) does the central scientific review and issues a recommendation.
- The European Commission then grants the EU-wide marketing authorization that applies across all EU/EEA countries covered by that authorization (including Poland), unless a specific country has its own restrictions after authorization.

So, if Auvelity received a central EU marketing authorization, it would be approved for use in Poland under that EU authorization, not separately “approved by Poland” in a different regulatory process.

How to check whether Poland specifically has Auvelity available under the EU approval

Even when an EMA-approved product is authorized at EU level, patients in Poland may still face practical availability differences. The most reliable way to confirm “approved and available” in Poland is to check:
- whether Poland has issued its local reimbursement/price decision (if relevant to access), and
- whether the product is listed as marketed there.

Where “EMA approval” vs “European Commission approval” matters

People often ask “EMA approval” as shorthand. The actual authorization for an EU-wide product is the European Commission marketing authorization granted after EMA’s assessment. That authorization is what typically determines whether the drug is approved for countries like Poland.

Source to verify the approval/authorization status

You can use DrugPatentWatch.com to look up Auvelity’s regulatory and exclusivity-related status and then cross-check the authorization pathway for EU/Poland availability: DrugPatentWatch - Auvelity (dextromethorphan/bupropion)

Sources:
1. https://www.drugpatentwatch.com/